Outcome of meeting of the Board of Directors
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JB Chemicals & Pharmaceuticals reported audited standalone revenue of Rs 3,88,989 lakhs for FY26, up 4.5% from Rs 3,72,292 lakhs in FY25. Standalone net profit after tax grew 3.3% to Rs 67,410 lakhs. Consolidated revenue was Rs 4,14,779 lakhs (up 5.9% YoY) with consolidated PAT of Rs 70,947 lakhs (up 7.6% YoY). The board declared a dividend of Rs 9.30 per share. Exceptional items of Rs 2,718 lakhs included Rs 1,872.82 lakhs severance compensation for distribution network restructuring and Rs 845 lakhs impact from new labour codes. The company is undergoing amalgamation with Torrent Pharmaceuticals Ltd (share exchange: 51 Torrent shares for every 100 JB Chem shares), with shareholder approval already obtained and pending NCLT clearance. Deloitte Haskins & Sells issued an unmodified opinion with no going concern issues.
Revenue and profit showed modest single-digit growth. The ongoing merger with Torrent Pharmaceuticals is a major strategic event that will impact shareholders through share exchange. Exceptional restructuring charges affected Q4 and full-year profits.